Trial Profile
Phase II dose confirmation trial of mocetinostat in combination with azacitidine in patients with myelodysplastic syndromes (MDS).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2014
Price :
$35
*
At a glance
- Drugs Mocetinostat (Primary) ; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Mirati Therapeutics
- 15 May 2014 According to a Mirati Therapeutics media release, initial data are expected by the end of 2014.
- 07 Apr 2014 New trial record
- 17 Mar 2014 Mirati Therapeutics conducts a phase II dose confirmation trial of mocetinostat in combination with azacitidine in patients with myelodysplastic syndromes, according to a Mirati Therapeutics media release.